Key Points
-
Contrary to the reverse epidemiology of hypertension as assessed by peridialytic blood pressure (BP) recordings, interdialytic BP assessed either by home or ambulatory BP monitoring is linearly associated with an increased risk of all-cause and cardiovascular mortality
-
Routine BP recordings obtained before or after dialysis sessions display high variability, poor reproducibility and provide inaccurate estimates of the interdialytic BP burden; out-of-dialysis BP monitoring improves the accuracy of hypertension diagnoses among dialysis patients
-
Rather than initiating or intensifying antihypertensive drug therapy, management of hypertension among dialysis patients should initially involve strict control of sodium and volume excess
-
Restricting dietary sodium intake, individualizing dialysate sodium, avoiding use of short dialysis sessions and probing of dry weight represent the major non-pharmacological interventions to control volume excess
-
Antihypertensive drug therapy is necessary when BP remains uncontrolled despite the optimal management of volume; with the exception of diuretics, all major antihypertensive classes are useful in treating hypertension in patients on dialysis
-
Choice of the appropriate antihypertensive regimen should be individualized and based on the BP-lowering efficacy, cardioprotective properties, intradialytic and interdialytic pharmacokinetics and adverse-effect profiles of the agents; β-blockers, particularly atenolol, or long-acting calcium-channel blockers are reasonable options
Abstract
The diagnosis and management of hypertension among patients on chronic dialysis is challenging. Routine peridialytic blood pressure recordings are unable to accurately diagnose hypertension and stratify cardiovascular risk. By contrast, blood pressure recordings taken outside the dialysis setting exhibit clear prognostic associations with survival and might facilitate the diagnosis and long-term management of hypertension. Once accurately diagnosed, management of hypertension in individuals on chronic dialysis should initially involve non-pharmacological strategies to control volume overload. Accordingly, first-line strategies should focus on achieving dry weight, individualizing dialysate sodium concentrations and ensuring dialysis sessions are at least 4 h in duration. If blood pressure remains unresponsive to volume management strategies, pharmacological treatment is required. The choice of appropriate antihypertensive regimen should be individualized taking into account the efficacy, safety, and pharmacokinetic properties of the antihypertensive medications as well as any comorbid conditions and the overall risk profile of the patient. In contrast to their effects in the general hypertensive population, emerging evidence suggests that β-blockers might offer the greatest cardioprotection in hypertensive patients on dialysis. In this Review, we discuss estimates of the epidemiology of hypertension in the dialysis population as well as the challenges in diagnosing and managing hypertension among these patients.
Similar content being viewed by others
References
Lim, S. S., Vos, T., Flaxman, A. D. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224–2260 (2012).
Perkovic, V., Huxley, R., Wu, Y., Prabhakaran, D. & MacMahon, S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 50, 991–997 (2007).
Port, F. K., Hulbert-Shearon, T. E., Wolfe, R. A. et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am. J. Kidney Dis. 33, 507–517 (1999).
Zager, P.G., Nikolic, J., Brown, R.H. et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 54, 561–569 (1998).
Agarwal, R. Blood pressure and mortality among hemodialysis patients. Hypertension 55, 762–768 (2010).
Alborzi, P., Patel, N. & Agarwal, R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin. J. Am. Soc. Nephrol. 2, 1228–1234 (2007).
Amar, J. et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int. 57, 2485–2491 (2000).
Agarwal, R. & Sinha, A. D. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 53, 860–866 (2009).
Heerspink, H. J. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373, 1009–1015 (2009).
Agarwal, R. & Weir, M. R. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 5, 1255–1260 (2010).
Agarwal, R. et al. Assessment and management of hypertension in patients on dialysis. J. Am. Soc. Nephrol. 25, 1630–1646 (2014).
Denker, M. G. & Cohen, D. L. Antihypertensive medications in end-stage renal disease. Semin. Dial. 28, 330–336 (2015).
Agarwal, R. Pro: ambulatory blood pressure should be used in all patients on hemodialysis. Nephrol. Dial. Transplant. 30, 1432–1437 (2015).
Rohrscheib, M. R., Myers, O. B., Servilla, K. S. et al. Age-related blood pressure patterns and blood pressure variability among hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1407–1414 (2008).
Rahman, M., Fu, P., Sehgal, A. R. & Smith, M. C. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am. J. Kidney Dis. 35, 257–265 (2000).
Rocco, M. V., Yan, G., Heyka, R. J., Benz, R. & Cheung, A. K. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am. J. Nephrol. 21, 280–288 (2001).
Salem, M. M. Hypertension in the hemodialysis population: a survey of 649 patients. Am. J. Kidney Dis. 26, 461–468 (1995).
Agarwal, R. et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med. 115, 291–297 (2003).
Agarwal, R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am. J. Nephrol. 34, 381–390 (2011).
Agarwal, R., Bouldin, J. M., Light, R. P. & Garg, A. Inferior vena cava diameter and left atrial diameter measure volume but not dry weight. Clin. J. Am. Soc. Nephrol. 6, 1066–1072 (2011).
Agarwal, R., Peixoto, A. J., Santos, S. F. & Zoccali, C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin. J. Am. Soc. Nephrol. 1, 389–398 (2006).
Agarwal, R. & Lewis, R. R. Prediction of hypertension in chronic hemodialysis patients. Kidney Int. 60, 1982–1989 (2001).
Rahman, M. et al. A comparison of standardized versus “usual” blood pressure measurements in hemodialysis patients. Am. J. Kidney Dis. 39, 1226–1230 (2002).
Agarwal, R., Andersen, M. J., Bishu, K. & Saha, C. Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int. 69, 900–906 (2006).
Agarwal, R., Brim, N. J., Mahenthiran, J., Andersen, M. J. & Saha, C. Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension 47, 62–68 (2006).
Moriya, H., Ohtake, T. & Kobayashi, S. Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAB) in patients on haemodialysis. Nephrol. Dial. Transplant. 22, 1198–1204 (2007).
Moriya, H. et al. Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients. Clin. J. Am. Soc. Nephrol. 3, 416–422 (2008).
Agarwal, R. Managing hypertension using home blood pressure monitoring among haemodialysis patients—a call to action. Nephrol. Dial Transplant 25, 1766–1771 (2010).
Agarwal, R., Metiku, T., Tegegne, G. G. et al. Diagnosing hypertension by intradialytic blood pressure recordings. Clin. J. Am. Soc. Nephrol. 3, 1364–1372 (2008).
Agarwal, R. et al. Home blood pressure measurements for managing hypertension in hemodialysis patients. Am. J. Nephrol. 30, 126–134 (2009).
da Silva, G. V. et al. Home blood pressure monitoring in blood pressure control among haemodialysis patients: an open randomized clinical trial. Nephrol. Dial. Transplant. 24, 3805–3811 (2009).
Kauric-Klein, Z. & Artinian, N. Improving blood pressure control in hypertensive hemodialysis patients. CANNT J. 17, 24–26 (2007).
Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N. & Tegegne, G. G. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol. Dial. Transplant. 29, 672–681 (2014).
Pickering, T. G., Shimbo, D. & Haas, D. Ambulatory blood-pressure monitoring. N. Engl. J. Med. 354, 2368–2374 (2006).
Agarwal, R., Andersen, M. J. & Light, R. P. Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am. J. Nephrol. 28, 210–217 (2008).
Bansal, N. et al. Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension 65, 93–100 (2015).
de la Sierra, A. et al. Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile? Am. J. Hypertens. 27, 680–687 (2014).
Fan, H. Q. et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J. Hypertens. 28, 2036–2045 (2010).
Zoccali, C. et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int. 53, 1078–1084 (1998).
Zoccali, C., Tripepi, R., Torino, C., Tripepi, G. & Mallamaci, F. Moderator's view: ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients. Nephrol. Dial. Transplant. 30, 1443–1448 (2015).
Bishu, K., Gricz, K. M., Chewaka, S. & Agarwal, R. Appropriateness of antihypertensive drug therapy in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 1, 820–824 (2006).
Mc Causland, F. R., Waikar, S. S. & Brunelli, S. M. Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients. Kidney Int. 82, 204–211 (2012).
Maduell, F. & Navarro, V. Dietary salt intake and blood pressure control in haemodialysis patients. Nephrol. Dial. Transplant. 15, 2063 (2000).
Kooman, J. P., van der Sande, F., Leunissen, K. & Locatelli, F. Sodium balance in hemodialysis therapy. Semin. Dial 16, 351–355 (2003).
Agarwal, R., Alborzi, P., Satyan, S. & Light, R. P. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 53, 500–507 (2009).
Bibbins-Domingo, K., Chertow, G. M., Coxson, P. G. et al. Projected effect of dietary salt reductions on future cardiovascular disease. N. Engl. J. Med. 362, 590–599 (2010).
Kayikcioglu, M. et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol. Dial. Transplant. 24, 956–962 (2009).
Ozkahya, M. et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J. Nephrol. 15, 655–660 (2002).
Lynch, K. E., Lynch, R., Curhan, G. C. & Brunelli, S. M. Altered taste perception and nutritional status among hemodialysis patients. J. Ren Nutr. 23, 288–295 (2013).
Munoz, M. J., Arramreddy, R. & Schiller, B. Dialysate sodium: choosing the optimal hemodialysis bath. Am. J. Kidney Dis. 66, 710–720 (2015).
Santos, S. F. & Peixoto, A. J. Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 522–530 (2008).
Weiner, D. E. et al. Improving clinical outcomes among hemodialysis patients: a proposal for a “volume first” approach from the chief medical officers of US dialysis providers. Am. J. Kidney Dis. 64, 685–695 (2014).
Van Stone, J. C., Bauer, J. & Carey, J. The effect of dialysate sodium concentration on body fluid compartment volume, plasma renin activity and plasma aldosterone concentration in chronic hemodialysis patients. Am. J. Kidney Dis. 2, 58–64 (1982).
Flanigan, M. J., Khairullah, Q. T. & Lim, V. S. Dialysate sodium delivery can alter chronic blood pressure management. Am. J. Kidney Dis. 29, 383–391 (1997).
Hecking, M. et al. Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 59, 238–248 (2012).
Waikar, S. S., Curhan, G. C. & Brunelli, S. M. Mortality associated with low serum sodium concentration in maintenance hemodialysis. Am. J. Med. 124, 77–84 (2011).
Arramreddy, R., Sun, S. J., Munoz, M. J., Chertow, G. M. & Schiller, B. Individualized reduction in dialysate sodium in conventional in-center hemodialysis. Hemodial. Int. 16, 473–480 (2012).
de Paula, F. M. et al. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int. 66, 1232–1238 (2004).
Gumrukcuoglu, H. A. et al. Effects of lowering dialysate sodium on carotid artery atherosclerosis and endothelial dysfunction in maintenance hemodialysis patients. Int. Urol. Nephrol. 44, 1833–1839 (2012).
Inrig, J. K. et al. Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoregulators during hemodialysis: a randomized crossover study. Am. J. Kidney Dis. 65, 464–473 (2014).
Thein, H., Haloob, I. & Marshall, M. R. Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain. Nephrol. Dial. Transplant. 22, 2630–2639 (2007).
Zhou, Y. L., Liu, J., Ma, L. J. et al. Effects of increasing diffusive sodium removal on blood pressure control in hemodialysis patients with optimal dry weight. Blood Purif. 35, 209–215 (2013).
Song, J. H., Lee, S. W., Suh, C. K. & Kim, M. J. Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling hemodialysis. Am. J. Kidney Dis. 40, 291–301 (2002).
Song, J. H. et al. Effect of sodium balance and the combination of ultrafiltration profile during sodium profiling hemodialysis on the maintenance of the quality of dialysis and sodium and fluid balances. J. Am. Soc. Nephrol. 16, 237–246 (2005).
Sinha, A. D. & Agarwal, R. Can chronic volume overload be recognized and prevented in hemodialysis patients? The pitfalls of the clinical examination in assessing volume status. Semin. Dial. 22, 480–482 (2009).
Sinha, A. D. Why assistive technology is needed for probing of dry weight. Blood Purif. 31, 197–202 (2011).
Agarwal, R., Andersen, M. J. & Pratt, J. H. On the importance of pedal edema in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 153–158 (2008).
Sinha, A. D., Light, R. P. & Agarwal, R. Relative plasma volume monitoring during hemodialysis AIDS the assessment of dry weight. Hypertension 55, 305–311 (2010).
Hur, E. et al. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am. J. Kidney Dis. 61, 957–965 (2013).
Machek, P., Jirka, T., Moissl, U., Chamney, P. & Wabel, P. Guided optimization of fluid status in haemodialysis patients. Nephrol. Dial. Transplant. 25, 538–544 (2010).
Onofriescu, M. et al. Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. Int. Urol. Nephrol. 44, 583–591 (2012).
Zoccali, C. et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 65, 1492–1498 (2004).
Agarwal, R., Bouldin, J. M., Light, R. P. & Garg, A. Probing dry-weight improves left ventricular mass index. Am. J. Nephrol. 33, 373–380 (2011).
Georgianos, P. I. & Agarwal, R. Relative importance of aortic stiffness and volume as predictors of treatment-induced improvement in left ventricular mass index in dialysis. PLoS ONE 10, e0135457 (2015).
Wizemann, V. et al. The mortality risk of overhydration in haemodialysis patients. Nephrol. Dial. Transplant. 24, 1574–1579 (2009).
Agarwal, R. Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension 56, 512–517 (2010).
Reddan, D. N. et al. Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. J. Am. Soc. Nephrol. 16, 2162–2169 (2005).
Onofriescu, M. et al. Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. Am. J. Kidney Dis. 64, 111–118 (2014).
Jansen, M. A. et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 62, 1046–1053 (2002).
Shafi, T., Jaar, B. G., Plantinga, L. C. et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the choices for healthy outcomes in caring for end-stage renal disease (CHOICE) study. Am. J. Kidney Dis. 56, 348–358 (2010).
Foley, R. N., Gilbertson, D. T., Murray, T. & Collins, A. J. Long interdialytic interval and mortality among patients receiving hemodialysis. N. Engl. J. Med. 365, 1099–1107 (2011).
Tandon, T., Sinha, A. D. & Agarwal, R. Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure. Nephrol. Dial. Transplant. 28, 1562–1568 (2013).
Brunet, P. et al. Tolerance of haemodialysis: a randomized cross-over trial of 5-h versus 4-h treatment time. Nephrol. Dial. Transplant. 11 (Suppl. 8), 46–51 (1996).
Chertow, G. M., Levin, N. W., Beck, G. J. et al. In-center hemodialysis six times per week versus three times per week. N. Engl. J. Med. 363, 2287–2300 (2010).
Georgianos, P. I., Sarafidis, P. A., Sinha, A. D. & Agarwal, R. Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals? Am. J. Nephrol. 41, 400–408 (2015).
Ok, E. et al. Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study. Nephrol. Dial. Transplant. 26, 1287–1296 (2011).
Tattersall, J. et al. EBPG guideline on dialysis strategies. Nephrol. Dial. Transplant. 22 (Suppl 2), ii5–21 (2007).
Hayashi, S. Y. et al. Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: a tissue Doppler study. Nephrol. Dial. Transplant. 23, 1355–1361 (2008).
Lemes, H. P. et al. Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis. Clin. Exp. Nephrol. 15, 554–559 (2011).
Zannad, F. et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 70, 1318–1324 (2006).
Takahashi, A. et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. Nephrol. Dial. Transplant. 21, 2507–2512 (2006).
Suzuki, H. et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am. J. Kidney Dis. 52, 501–506 (2008).
Tai, D. J. et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin. J. Am. Soc. Nephrol. 5, 623–630 (2010).
Iseki, K. et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol. Dial. Transplant. 28, 1579–1589 (2013).
Yang, L. Y., Ge, X., Wang, Y. L. et al. Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis. Am. J. Med. Sci. 345, 1–9 (2013).
Peters, C. D., Kjaergaard, K. D., Jensen, J. D. et al. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int. 86, 625–637 (2014).
Zoccali, C. & Mallamaci, F. Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality? Kidney Int. 86, 469–471 (2014).
Sanghavi, S., Whiting, S. & Uribarri, J. Potassium balance in dialysis patients. Semin. Dial. 26, 597–603 (2013).
Hatch, M., Freel, R. W. & Vaziri, N. D. Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure. Am. J. Physiol. 274, F275–F282 (1998).
Martin, R. S. et al. Increased secretion of potassium in the rectum of humans with chronic renal failure. Am. J. Kidney Dis. 8, 105–110 (1986).
Knoll, G. A. et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am. J. Med. 112, 110–114 (2002).
Inrig, J. K. Antihypertensive agents in hemodialysis patients: a current perspective. Semin. Dial. 23, 290–297 (2010).
Levin, N. W., Kotanko, P., Eckardt, K. U. et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 77, 273–284 (2010).
Cice, G. et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J. Am. Coll. Cardiol. 41, 1438–1444 (2003).
Georgianos, P. I. & Agarwal, R. Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 10, 639–645 (2015).
Tan, I., Butlin, M., Liu, Y. Y., Ng, K. & Avolio, A. P. Heart rate dependence of aortic pulse wave velocity at different arterial pressures in rats. Hypertension 60, 528–533 (2012).
Wilkinson, I. B. et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am. J. Hypertens. 15, 24–30 (2002).
Swierblewska, E. et al. An independent relationship between muscle sympathetic nerve activity and pulse wave velocity in normal humans. J. Hypertens. 28, 979–984 (2010).
Roberts, M. A., Pilmore, H. L., Ierino, F. L. et al. The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: a randomized controlled trial. Am. J. Kidney Dis. 67, 902–911 (2015).
Weir, M. A., Dixon, S. N., Fleet, J. L. et al. β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J. Am. Soc. Nephrol. 26, 987–996 (2015).
Tepel, M., Hopfenmueller, W., Scholze, A., Maier, A. & Zidek, W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol. Dial. Transplant. 23, 3605–3612 (2008).
Aslam, S., Santha, T., Leone, A. & Wilcox, C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 70, 2109–2115 (2006).
London, G. M., Marchais, S. J., Guerin, A. P. et al. Salt and water retention and calcium blockade in uremia. Circulation 82, 105–113 (1990).
Matsumoto, Y. et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J. Am. Coll. Cardiol. 63, 528–536 (2014).
Lin, C., Zhang, Q., Zhang, H. & Lin, A. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study. J Clin Hypertens (Greenwich) 18, 121–128 (2016).
US National Library of Medicine. ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT01848639 (2016).
Georgianos, P. I., Sarafidis, P. A., Liakopoulos, V., Balaskas, E. V. & Zebekakis, P. E. Mineralocorticoid receptor antagonism for cardiovascular protection in end-stage renal disease: new data but the controversy continues. J. Clin. Hypertens. (Greenwich) 18, 197–199 (2015).
Aybal, K. A. et al. Effects of lowering dialysate sodium on flow-mediated dilatation in patients with chronic kidney disease. Nephrol. Dial. Transplant. 26, 3678–3682 (2011).
Munoz, M. J., Bayes, L. Y., Sun, S., Doss, S. & Schiller, B. Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement study. Am. J. Kidney Dis. 58, 956–963 (2011).
Acknowledgements
R.A. is supported by NIH 5R01-HL126901 and a grant from VA Merit Review 5I01CX000829-04.
Author information
Authors and Affiliations
Contributions
P.I.G. drafted the first version of the article under the supervision of R.A. R.A. revised the manuscript and modified it significantly before submission.
Corresponding author
Ethics declarations
Competing interests
R.A. has consulted for Abbvie, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Celgene, Daiichi Sankyo Inc, Eli Lilly, Gilead, Glaxosmithkine, Johnson & Johnson, Merck, Novartis, Sandoz, Relypsa, and ZS Pharma. P.I.G. declares no competing interests.
Glossary
- Peridialytic BP
-
Blood pressure recordings obtained by the dialysis-unit staff shortly before and/or after the dialysis session.
- Interdialytic BP
-
Blood pressure recordings obtained outside of the dialysis unit either with the use of home or ambulatory blood pressure monitoring.
- Ambulatory BP monitoring
-
An automated method to measure blood pressure that uses an oscillometric device to typically record blood pressure 2–3 times per hour over an entire interdialytic interval. Averaged readings are considered the reference standard for true blood pressure.
- Intradialytic BP
-
Blood pressure recordings obtained typically every 30 minutes during dialysis using an automated cuff attached to the dialysis machine.
- Dry-weight probing
-
The iterative process of gently and gradually reducing postdialysis weight by setting the ultrafiltration goal to just a little below the previously achieved postdialysis weight; this process requires the assessment of intradialytic and interdialytic symptoms and signs of hypervolaemia or hypovolaemia.
- Dry weight
-
The lowest tolerated postdialysis weight achieved at which minimal signs or symptoms of either hypovolaemia or hypervolaemia exist
- Sodium-profiling dialysis
-
Time-dependent modification of the sodium concentration in the dialysate over the course of the dialysis session.
- RPV monitoring
-
Continuous noninvasive measurement of the haematocrit level during dialysis using photo-optical technology to assess changes in intravascular blood volume with ultrafiltration.
- Bioelectrical impedence analysis
-
A non-invasive method to estimate body composition and the relative pool sizes of total body water, extracellular fluid volume and intracellular fluid volume.
Rights and permissions
About this article
Cite this article
Georgianos, P., Agarwal, R. Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol 12, 636–647 (2016). https://doi.org/10.1038/nrneph.2016.129
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.129
- Springer Nature Limited
This article is cited by
-
Regional variation in pre-dialysis blood pressure and its association with cardiovascular mortality rates in Japanese patients undergoing dialysis
Hypertension Research (2024)
-
Prescribing the optimal dialysate sodium concentration for managing hypertension and volume overload in hemodialysis: one size does not fit to all patients
Journal of Human Hypertension (2023)
-
Does Renal Denervation a Reasonable Treatment Option in Hemodialysis-Dependent Patient with Resistant Hypertension? A Narrative Review
Current Hypertension Reports (2023)
-
The relationship between the prognostic nutritional index and new-onset pneumonia in peritoneal dialysis patients
International Urology and Nephrology (2022)
-
Arterial stiffness in end-stage renal disease—pathogenesis, clinical epidemiology, and therapeutic potentials
Hypertension Research (2018)